Michael Burgess, MD, PhD
Volunteer Assistant Clinical Professor
Medicine
School of Medicine

Education & Training

Show all (5) Hide

• Fellowship Hematology and Medical Oncology University of California, San Francisco 2012
• Residency Internal Medicine University of California, San Francisco 2009
• M.D. Medicine David Geffen School of Medicine at UCLA 2007
• Ph.D. Molecular Biology University of California, Los Angeles 2005
• B.A. Molecular and Cell Biology University of California, Berkeley 1997

Interests

Show all (6) Hide

• Multiple Myeloma
• Early Clinical Development
• Biomarker Discovery
• Myelodysplastic Syndromes
• Acute Myeloid Leukemia
• Lymphoma

Publications (15)

Top publication keywords:
Antineoplastic AgentsCD3 ComplexMultiple MyelomaMonomeric GTP-Binding ProteinsDiphenylamineDrug Resistance, NeoplasmFusion Proteins, bcr-ablBenzamidesMyelodysplastic SyndromesMAP Kinase Kinase KinasesProto-Oncogene Proteins p21(ras)MAP Kinase Signaling SystemLeukemia, Myeloid, AcuteB-Cell Maturation AntigenHematopoietic Stem Cells

• Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.
  Leukemia 2026 Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L, Namburi S, Ribas P, Santoro A, Rodriguez-Otero P, Creignou M, Chen J, Cao C, Kiesel B, Gaudy A, Thompson EG, Shen Y, Zarif S, Hsu K, …
• Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling.
  bioRxiv : the preprint server for biology 2025 Huang BJ, D'Souza J, Batingana AR, Harris MD, Wang X, Hwang E, Wandler AM, Burgess MR, Li Q, Meshinchi S, Bollag G, Shannon K
• Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma.
  Leukemia 2025 Ravi G, Richard S, Kumar S, Atrash S, Liedtke M, Kaur G, Derman B, Bergsagel PL, Mailankody S, McCarthy P, Shrestha A, Kelly LM, Ly T, Das S, Thorpe J, Maier A, Varun D, Navarro G, Burgess MR, Hege K,…
• Informing the Recommended Phase III Dose of Alnuctamab, a CD3?×?BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis.
  Clinical pharmacology and therapeutics 2024 Kiesel B, Osawa M, Masilamani M, Bar M, Hsu K, Godwin C, Burgess M, Lamba M, Gaudy A
• Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
  Annals of hematology 2022 Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W

Show all (10 more) Hide

• Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
  Blood 2018 An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME
• KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
  Cell 2017 Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor …
• The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
  Nature medicine 2017 Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, …
• Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.
  eLife 2015 Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K
• Preclinical efficacy of MEK inhibition in Nras-mutant AML.
  Blood 2014 Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q
• MAGI-2 scaffold protein is critical for kidney barrier function.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers CL
• PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
  Science signaling 2013 Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K
• Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
  Proceedings of the National Academy of Sciences of the United States of America 2006 Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG
• Treating imatinib-resistant leukemia: the next generation targeted therapies.
  TheScientificWorldJournal 2006 Burgess MR, Sawyers CL
• Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.
  Proceedings of the National Academy of Sciences of the United States of America 2005 Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL